Forbes December 1, 2025
A late stage trial for an investigational malaria drug called GanLum (ganaplacide/lumefantrine) has demonstrated a 97.4% cure rate, outperforming currently existing treatments. The drug is being developed by the pharmaceutical firm Novartis in collaboration with a not-for-profit foundation called the Medicines for Malaria Venture. If approved, GanLum will be considered an important advance against treatment-resistant malaria strains.
Malaria is a mosquito-borne disease which carries with it a particularly high disease burden in children in Africa. In the 20th century alone, malaria claimed between 150 and 300 million lives globally. Annually, nearly 600,000 people die from the communicable disease worldwide, more than 500,000 of whom are in Africa. The vast majority of victims are younger than five years old.
Since around...
Today's Sponsors
Today's Sponsor